Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow?
Circulating tumor DNA (ctDNA) is emerging as a minimally invasive biomarker for risk stratification and treatment-response assessment in lung cancer immunotherapy, but its routine use for treatment selection has not been established. This review critic…